MA51658A - Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies - Google Patents
Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathiesInfo
- Publication number
- MA51658A MA51658A MA051658A MA51658A MA51658A MA 51658 A MA51658 A MA 51658A MA 051658 A MA051658 A MA 051658A MA 51658 A MA51658 A MA 51658A MA 51658 A MA51658 A MA 51658A
- Authority
- MA
- Morocco
- Prior art keywords
- synucleinopathies
- antagonist
- treatment
- association including
- association
- Prior art date
Links
- 208000032859 Synucleinopathies Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483555P | 2017-04-10 | 2017-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51658A true MA51658A (fr) | 2020-12-02 |
Family
ID=63792736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051658A MA51658A (fr) | 2017-04-10 | 2018-04-09 | Association comprenant un antagoniste de nk1 et méthode de traitement de synucléinopathies |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11160809B2 (fr) |
| EP (2) | EP3609495B1 (fr) |
| JP (1) | JP7271437B2 (fr) |
| KR (1) | KR20200002899A (fr) |
| CN (1) | CN110730662A (fr) |
| AU (1) | AU2018251604B2 (fr) |
| BR (1) | BR112019021125A2 (fr) |
| EA (1) | EA201992414A1 (fr) |
| ES (1) | ES2986644T3 (fr) |
| HU (1) | HUE068710T2 (fr) |
| IL (3) | IL312486B2 (fr) |
| MA (1) | MA51658A (fr) |
| MX (1) | MX394351B (fr) |
| TW (1) | TWI803488B (fr) |
| WO (1) | WO2018191160A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018258117A1 (en) | 2017-04-24 | 2019-12-12 | Chase Therapeutics Corporation | Compositions and method for treating depression |
| AU2018290889B2 (en) * | 2017-06-30 | 2024-06-27 | Alto Neuroscience, Inc. | NK-1 antagonist compositions and methods for use in treating depression |
| PH12022551608A1 (en) | 2019-12-31 | 2023-10-16 | Chase Therapeutics Corp | Kinases as biomarkers for neurodegenerative conditions |
| EP4297868A4 (fr) * | 2021-02-23 | 2025-01-08 | Hoth Therapeutics, Inc. | Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572485D1 (en) | 1984-12-22 | 1989-09-28 | Thomae Gmbh Dr K | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs |
| BR9206073A (pt) | 1991-05-31 | 1994-12-06 | Pfizer | Derivados de quinuclidina |
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| DE4241013A1 (de) * | 1992-12-05 | 1994-06-09 | Boehringer Ingelheim Kg | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| WO1998024446A1 (fr) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Utilisation d'antagonistes du recepteur nk-1 dans le traitement des diskynesies |
| DE19830201A1 (de) * | 1998-07-07 | 2000-01-13 | Boehringer Ingelheim Pharma | Mittel mit antidepressiver Wirkung |
| CA2301899C (fr) * | 1998-07-27 | 2008-11-18 | Boehringer Ingelheim Pharma Kg | Agent antidepresseur |
| EP1035115B1 (fr) | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1 |
| GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| PT1303490E (pt) | 2000-07-14 | 2008-09-04 | Hoffmann La Roche | Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina |
| GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| DK1349541T3 (da) | 2000-12-14 | 2007-01-08 | Hoffmann La Roche | Selvemulgerende lipidmatrix (SELM) |
| PE20030762A1 (es) * | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
| GB0310881D0 (en) * | 2003-05-12 | 2003-06-18 | Merck Sharp & Dohme | Pharmaceutical formulation |
| TWI341198B (en) | 2004-01-27 | 2011-05-01 | Merck Sharp & Dohme | Hydroisoindoline tachykinin receptor antagonists |
| HUE034099T2 (en) | 2004-01-30 | 2018-01-29 | Zoetis Services Llc | Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms |
| US20120253047A1 (en) | 2004-03-19 | 2012-10-04 | Dipharma S.P.A. | Process for the preparation of (r)-pramipexole |
| NZ556628A (en) * | 2005-03-08 | 2009-09-25 | Janssen Pharmaceutica Nv | Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists |
| JP2009500452A (ja) | 2005-07-11 | 2009-01-08 | メルク エンド カムパニー インコーポレーテッド | ヒドロイソインドリンタキキニン受容体アンタゴニストの製造方法 |
| ATE444750T1 (de) | 2005-08-15 | 2009-10-15 | Univ Virginia | Neurorestauration mit r(+) pramipexol |
| US8518926B2 (en) | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
| CN102160865A (zh) | 2006-05-16 | 2011-08-24 | 诺普神经科学股份有限公司 | R(+)和s(-)普拉克索的组合物以及使用该组合物的方法 |
| CN101641096A (zh) * | 2006-12-14 | 2010-02-03 | 诺普神经科学股份有限公司 | (r)-普拉克索的组合物以及使用该组合物的方法 |
| CN101677564A (zh) | 2007-03-14 | 2010-03-24 | 诺普神经科学股份有限公司 | (6r)-4,5,6,7-四氢-n6-丙基-2,6-苯并噻唑-二胺的改良释放制剂及其使用方法 |
| US20080254117A1 (en) | 2007-04-10 | 2008-10-16 | Noel Cotton | Process for preparing pramipexole dihydrochloride tablets |
| GB0806652D0 (en) | 2008-04-11 | 2008-05-14 | Glaxo Group Ltd | Anhydrous crystal form of orvepitant maleate |
| EP2464230B1 (fr) | 2009-08-14 | 2016-10-05 | OPKO Health, Inc. | Formulations intraveineuses de rolapitant |
| EP2722045B1 (fr) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions pour traiter les nausées et vomissements à médiation centrale |
| WO2012140604A1 (fr) | 2011-04-15 | 2012-10-18 | Sandoz Ag | Formulations stables de chlorhydrate de pramipexole |
| WO2012175434A1 (fr) | 2011-06-20 | 2012-12-27 | Glaxo Group Limited | Formulations pharmaceutiques comprenant du vestipitant |
| JP2016532660A (ja) | 2013-10-08 | 2016-10-20 | イノファーマ インク | アプレピタント経口液体製剤 |
| WO2016044784A1 (fr) | 2014-09-19 | 2016-03-24 | Heron Therapeutics, Inc. | Formulations d'émulson d'aprépitant |
| US9850267B2 (en) | 2015-06-03 | 2017-12-26 | Navinta, Llc | Crystalline fosaprepitant dicyclohexylamine salt and its preparation |
| NL2015865B1 (en) | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
| AU2018290889B2 (en) * | 2017-06-30 | 2024-06-27 | Alto Neuroscience, Inc. | NK-1 antagonist compositions and methods for use in treating depression |
-
2018
- 2018-04-08 IL IL312486A patent/IL312486B2/en unknown
- 2018-04-09 KR KR1020197033121A patent/KR20200002899A/ko not_active Withdrawn
- 2018-04-09 EA EA201992414A patent/EA201992414A1/ru unknown
- 2018-04-09 EP EP18785191.0A patent/EP3609495B1/fr active Active
- 2018-04-09 AU AU2018251604A patent/AU2018251604B2/en active Active
- 2018-04-09 JP JP2019555469A patent/JP7271437B2/ja active Active
- 2018-04-09 CN CN201880036987.9A patent/CN110730662A/zh active Pending
- 2018-04-09 US US16/604,468 patent/US11160809B2/en active Active
- 2018-04-09 IL IL309770A patent/IL309770B2/en unknown
- 2018-04-09 IL IL269875A patent/IL269875B2/en unknown
- 2018-04-09 ES ES18785191T patent/ES2986644T3/es active Active
- 2018-04-09 WO PCT/US2018/026699 patent/WO2018191160A1/fr not_active Ceased
- 2018-04-09 BR BR112019021125-0A patent/BR112019021125A2/pt not_active Application Discontinuation
- 2018-04-09 HU HUE18785191A patent/HUE068710T2/hu unknown
- 2018-04-09 MX MX2019012088A patent/MX394351B/es unknown
- 2018-04-09 MA MA051658A patent/MA51658A/fr unknown
- 2018-04-09 EP EP24189957.4A patent/EP4461362A3/fr active Pending
- 2018-04-10 TW TW107112324A patent/TWI803488B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| IL269875A (fr) | 2019-12-31 |
| EP4461362A3 (fr) | 2025-02-19 |
| IL312486B1 (en) | 2025-01-01 |
| AU2018251604A1 (en) | 2019-11-21 |
| US11160809B2 (en) | 2021-11-02 |
| US20200147097A1 (en) | 2020-05-14 |
| BR112019021125A2 (pt) | 2020-05-12 |
| IL309770A (en) | 2024-02-01 |
| CA3059418A1 (fr) | 2018-10-18 |
| JP7271437B2 (ja) | 2023-05-11 |
| TWI803488B (zh) | 2023-06-01 |
| CN110730662A (zh) | 2020-01-24 |
| KR20200002899A (ko) | 2020-01-08 |
| JP2020516625A (ja) | 2020-06-11 |
| HUE068710T2 (hu) | 2025-01-28 |
| TW201841634A (zh) | 2018-12-01 |
| IL269875B2 (en) | 2024-06-01 |
| IL312486B2 (en) | 2025-05-01 |
| EP3609495C0 (fr) | 2024-07-24 |
| MX394351B (es) | 2025-03-24 |
| ES2986644T3 (es) | 2024-11-12 |
| EA201992414A1 (ru) | 2020-03-16 |
| MX2019012088A (es) | 2020-02-07 |
| EP3609495A1 (fr) | 2020-02-19 |
| AU2018251604B2 (en) | 2022-04-14 |
| IL269875B1 (en) | 2024-02-01 |
| IL309770B2 (en) | 2025-02-01 |
| EP3609495A4 (fr) | 2020-12-02 |
| EP4461362A2 (fr) | 2024-11-13 |
| IL309770B1 (en) | 2024-10-01 |
| WO2018191160A1 (fr) | 2018-10-18 |
| EP3609495B1 (fr) | 2024-07-24 |
| IL312486A (en) | 2024-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3766431A4 (fr) | Dispositif médical et méthode de traitement | |
| EP3380121A4 (fr) | Méthode de traitement de troubles oculaires | |
| EP3779023A4 (fr) | Appareil de traitement de vêtements | |
| EP3706737A4 (fr) | Inhibiteurs de ash1l et méthodes de traitement comprenant ces derniers | |
| EP3634442A4 (fr) | Méthodes de traitement et de prévention de maladies | |
| EP3832004A4 (fr) | Appareil de traitement de vêtements | |
| EP3390634A4 (fr) | Compositions et méthodes pour le traitement de maladies oculaires | |
| EP3522934A4 (fr) | Compositions et méthode pour le traitement de la rénopathie | |
| EP3778649A4 (fr) | Méthode et composition de traitement de tumeurs | |
| EP3427678A4 (fr) | Dispositif médical et méthode de traitement | |
| EP3820461A4 (fr) | Méthode de traitement du cancer | |
| EP3273955A4 (fr) | Traitement de maladies respiratoires | |
| MA48730A (fr) | Compositions et méthodes de traitement de synucléinopathies | |
| IL269363A (en) | Methods for measuring therapeutic effects of retinal disease therapies | |
| MA46061A (fr) | Traitement ascaroside de maladies auto-immunes et inflammatoires | |
| EA201791901A1 (ru) | Антагонисты рецептора нейрокинина-3 для терапевтического или косметологического лечения излишних жировых отложений на теле | |
| EP3331499A4 (fr) | Composition et méthode de traitement de troubles métaboliques | |
| MA41462A (fr) | Méthode de traitement de maladies | |
| EP3448365A4 (fr) | Méthode de traitement de la constipation | |
| EP3344258A4 (fr) | Traitement de maladies auto-immunes et de maladies auto-inflammatoires | |
| EP3316887A4 (fr) | Inhibiteurs de gls1 pour le traitement de maladies | |
| EP3933099A4 (fr) | Appareil de traitement de vêtements | |
| EP3976829A4 (fr) | Méthode de traitement ou de prophylaxie | |
| EP3556380A4 (fr) | Méthode de prévention et de traitement de fibrose de tissu et d'organe | |
| EP3574003A4 (fr) | Méthode de traitement |